

Evolving Strategies in Epidemiologic Research on Radiation and Cancer

Authors: de González, Amy Berrington, Brenner, Alina, Hartge, Patricia, Lee, Choonsik, Morton, Lindsay, et al.

Source: Radiation Research, 176(4) : 527-532

Published By: Radiation Research Society

URL: <https://doi.org/10.1667/RRXX37.1>

BioOne Complete (complete.BioOne.org) is a full-text database of 200 subscribed and open-access titles in the biological, ecological, and environmental sciences published by nonprofit societies, associations, museums, institutions, and presses.

Your use of this PDF, the BioOne Complete website, and all posted and associated content indicates your acceptance of BioOne's Terms of Use, available at www.bioone.org/terms-of-use.

Usage of BioOne Complete content is strictly limited to personal, educational, and non - commercial use. Commercial inquiries or rights and permissions requests should be directed to the individual publisher as copyright holder.

BioOne sees sustainable scholarly publishing as an inherently collaborative enterprise connecting authors, nonprofit publishers, academic institutions, research libraries, and research funders in the common goal of maximizing access to critical research.

COMMENTARY

Evolving Strategies in Epidemiologic Research on Radiation and Cancer

Amy Berrington de González,¹ Alina Brenner, Patricia Hartge, Choonsik Lee, Lindsay Morton and Preetha Rajaraman

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

INTRODUCTION

With the emergence of new imaging technologies and expanded access to large administrative databases and biospecimen banks, research teams of radiation epidemiologists, dosimetrists, statisticians and related scientists are adapting their use of fundamental research strategies for studying radiation and cancer. Five broad strategies have yielded numerous critical insights in the last three decades: assessing risks from environmental radiation releases; projecting radiation risks; following patients who have had radiotherapy; estimating organ doses with more sophisticated phantom models; and focusing on genetically susceptible individuals. We consider these five approaches in turn and discuss how findings might provide insight into biological mechanisms and translate into clinical benefit and improved public health.

RADIATION RISK PROJECTION MODELING

Risk projection modeling makes use of the wealth of existing information on the long-term cancer risks after radiation exposure to project potential risks from specified exposure scenarios. Modeling allows for the timely estimation of risks and is particularly useful for low-dose scenarios because an infeasibly large sample size would be required to study these risks directly (1). It is not a new strategy; one of the earliest examples of its use was in the 1962 U.S. Federal Council Report on the health implications of exposure to fallout from above-ground nuclear testing. The committee estimated that there could be 0–2000 additional leukemia deaths in the U.S. as a result of these exposures (2). In recent years, however, risk projection modeling has moved from a rare to a ubiquitous strategy in radiation epidemiology. The reasons include the publication of user-friendly risk estimates for the U.S. population in the BEIR VII report and the increasing acceptance of the

limitations of epidemiological studies for elucidating risks from low-dose exposures directly. Applications of the approach vary widely; examples include estimation of the proportion of childhood leukemias attributable to background radiation exposure (3), the number of future cancers related to CT scans in the U.S. (4), and the risks to European countries from the Chernobyl accident (5).

The risk models used in these calculations rely most heavily upon the results from the Life Span Study of the Japanese atomic bomb survivors (6) because this is one of the few studies that can provide organ-specific risk models that account for age at exposure, time since exposure and sex. Breast and thyroid cancer risk models are the exception because they can make use of the pooled data from medically exposed populations (7, 8). Additional pooled models for other cancer sites will help to improve the modeling, for example, the planned pooling of a number of studies of brain cancer after radiation exposure. Further research into the joint effect of radiation and other cancer risk factors (e.g., smoking) could also improve the models by helping us understand how to transfer risk models from the Japanese atomic bomb survivors to the exposed population of interest, which typically has different “underlying” cancer rates. Because risk projection involves a large number of assumptions, we need to calculate the range of potential estimates under varying assumptions. Researchers at NCI and SENES Oak Ridge have developed an interactive risk calculator that formally incorporates and quantifies subjective uncertainties in the assumptions as well as statistical uncertainties in the model parameters. A web-based version of the software NCI RadRAT (Radiation Risk Assessment Tool) will be made publicly available later in 2011 (Fig. 1).

HYBRID COMPUTATIONAL PHANTOMS FOR RADIATION EXPOSURE RISK ASSESSMENT

Radiation dosimetry is a central component of radiation risk assessment. Organ- or tissue-specific estimated doses and associated uncertainties from large numbers of exposed individuals are essential for epidemiological studies of non-

¹ Address for correspondence: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; e-mail: berringtona@mail.nih.gov.

The screenshot shows the Radiation Risk Assessment Tool interface. At the top, there is a header with the National Cancer Institute logo and the text 'cancer.gov'. Below the header, there are navigation links: 'home', 'about NCI', 'cancer information', 'clinical trials', 'statistics', 'research programs', and 'research funding'. On the right side, there is a search box with options for 'dictionary', 'site map', and 'search'. The main content area is divided into three sections: 'Enter Input Information Manually' with fields for 'Run Identifier [optional]' (Run 1), 'Gender' (Male), 'Birth Year' (1950), and 'Number of Dose Entries' (1), along with buttons for 'Enter Doses' and 'Adv Settings'; 'Enter Input Information using a File' with an 'Upload Page' button; and 'Calculate Results' with an 'Estimate Risk' button. At the bottom, there is a footer with buttons for 'About Calculator', 'View Model Details', and 'Restart'.

FIG. 1. Radiation risk assessment tool.

uniform radiation exposure and provide the critical data required for modeling radiation dose response. There are two ways to determine organ doses in radiation exposure: measurement and calculation. Measurement consists of placing dosimeters in a physical phantom that represents a patient's body and then reading the dosimeters after irradiation under specified conditions. However, measurement can be very expensive, may require substantial man-hours of effort, and is not flexible because of the need for repeated irradiations under a wide range of conditions. By contrast, computer models of the human body, called computational human phantoms, and of radiation sources can be used to simulate the conditions of irradiation. Compared to measurement, calculation is cost-effective, requires fewer man-hours, and is much more flexible. Therefore, the estimations of organ dose rely heavily on the computer simulations in which computational human phantoms are used in combination with Monte Carlo radiation transport techniques.

The last 50 years have seen little change in the Monte Carlo transport algorithms, but the capacity and speed of the computation resources have undergone significant changes and notable expansion, and substantial improvements have been made in the computational human phantoms (Fig. 2). Computational phantoms have evolved from the 1950s when simple phantoms such as spheres, cylinders or their combinations were used. Stylized phantoms represented by

simple mathematical surface equations were introduced in the 1960s to describe human anatomy more realistically (9). Improved anatomical realism was achieved in the 1980s by voxel phantoms that were developed from the tomographic images from patients (10). Over time, the early crude general dosimetry, based on stylized phantoms, became more refined and dosimetry became more individualized. Despite the improved anatomical realism of voxel phantoms, the stylized phantom continues to be the basis of current dosimetry employed in epidemiological studies of medical exposures because a complete series of reference pediatric and adult voxel phantoms have not been available.

Recently, a new class of computational phantoms, hybrid phantoms, has been developed to take advantage of the mathematical flexibility and anatomical realism from both the stylized and voxel phantoms (11–13). Using a new mathematical format designated the Non-Uniform Rational B-Spline (NURBS), hybrid phantoms provide a high level of flexibility for modeling different body postures and sizes (Fig. 2). The hybrid phantoms also have more sophisticated anatomy (e.g., a detailed skeleton model) than the previous stylized and voxel phantoms. Hybrid phantoms have resolved several significant problems and provide more individualized organ dose estimations for persons of different ages and body dimensions (e.g., obese and thin individuals) and more accurate bone marrow dosimetry based on realistic skeleton models. The flexibility of the




FIG. 2. Evolution of phantoms.

hybrid phantoms, coupled with Monte Carlo transport technique, will provide more accurate dose estimates and improved characterization of uncertainty in those estimates. The greater accuracy in dose estimates should result in improved risk estimation in epidemiological studies, with estimates for uncertainty incorporated within the risk analysis.

INTENTIONAL AND ACCIDENTAL RELEASES OF RADIATION

The Life Span Study of Japanese atomic bomb survivors has taught us much of what we know about long-term risks from radiation exposures, especially at high dose rates. As of 2000, 45% of the cohort was alive. The number of deaths related to radiation in the survivors is estimated to peak around 2020. Ongoing follow-up and detailed risk assessment of the atomic bomb survivors will continue to add to knowledge about temporal patterns of radiation risk, organ-site-specific radiation risks, and interactions with non-radiation risk factors including smoking and other factors.

By following residents of the Techa River watershed who were exposed to releases of radionuclides from the Mayak nuclear facility, investigators are gleaning valuable information on the effects of radiation exposures that occurred at a low dose rate. Controversy remains with respect to how the same total dose affects radiation-related cancer risk at lower dose rates, and cohorts like the Techa River cohort provide the critically needed data.

The Chernobyl accident 25 years ago also provides extensive data on the effects of low-dose-rate exposure from radioactive fallout, including exposure to ^{131}I . In a recent cohort study of Ukrainian residents who were exposed as children or adolescents (14). NCI researches found evidence of a strong, linear dose response for thyroid cancer risk

using individual ^{131}I dose estimates (Fig. 3). The persisting elevation of thyroid cancer risk in this population underscores the need to continue to follow these individuals to assess whether the excess risk persists or declines with time. A case-control study of leukemia among clean-up workers who, unlike residents, received primarily whole-body protracted external radiation found a significant increase in risk of total leukemia with evidence of an increase in leukemias other than chronic lymphocytic leukemia and in chronic lymphocytic leukemia (15).

In short, we can use new dose estimation and new statistical techniques, but we need to continue tracking populations exposed to intentional or accidental releases of radiation, because such populations provide direct human data on exposure to radionuclides such as ^{131}I and the impact of dose-fractionation effects. Continued follow-up will improve the precision of radiation risk estimates and effect modifiers of radiation exposure. Pooled analyses combining data from several studies provide more precise risk estimates associated with different types of radiation, particularly for specific organ sites.

THERAPEUTIC RADIOTHERAPY AND CANCER RISK

Quantifying the contribution of radiotherapy to the risk of developing cancer not only provides vital information for patients who undergo such therapy and their physicians but also advances our understanding of the fundamental mechanisms of radiation carcinogenesis. Patients who receive therapeutic irradiation for various benign and malignant conditions experience a range of ionizing radiation exposures outside the treatment area due to scatter. The study of these exposures provides important insight into radiation-related carcinogenesis at radiation doses that often




FIG. 3. Dose–response relationship between incident thyroid cancers and ^{131}I dose estimates: A cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident in Ukraine. The solid line represents fitted relative risks (RR) based on the linear ERR model and the squares with vertical lines represent category specific RRs with 95% confidence intervals for mean ^{131}I dose per category. The fitted linear dose response was adjusted to pass through the lowest ^{131}I category. The ERR was adjusted for gender, oblast of residence at first screening examination, and continuous attained age.

are substantially higher than those in other settings (1–>40 Gy) but delivered in small fractions. Direct evaluation of the radiation dose–response relationship at these higher doses has proven critical, because a non-linear relationship has been shown to most accurately describe the data in this dose range (e.g., 1–>40 Gy) for certain malignancies, such as leukemia and thyroid cancer (16, 17). In addition, second cancers are a leading cause of morbidity and mortality among the nearly 12 million cancer survivors in the United States (18), yet data on the etiology of second cancers are sparse.

Measurement of cancer risks from radiotherapy has faced major challenges. To date, most studies of second cancers have been descriptive, often relying on data from population-based cancer registries. These studies have provided important evidence that cancer survivors typically have a higher risk of subsequent malignancy than the general population (19). However, because most descriptive studies are characterized by limited or no information on radiotherapy exposures, other treatments, or other cancer risk factors, their primary utility lies in identification of groups of cancer survivors at increased second cancer risk and generation of hypotheses that direct the development of specific analytic studies (20–22).

Medical record-based analytic studies overcome some of the limits of registry studies, and they have provided critical insights into the late effects of radiotherapy and chemotherapy. Although initial studies focused primarily on the most common radiation-induced malignancies (e.g., leukemia and cancers of the thyroid, breast and brain), recent

efforts have quantified the radiation dose–response relationship at higher doses for other cancer sites such as the lung (23–29). These studies also have provided key information on potential modifiers of radiation-related risks, such as age at exposure and cigarette smoking. Most analyses have found that the risks are lower than those observed after the single acute exposure in the Japanese atomic bomb survivors, though there is some suggestion that the joint effects of radiation and some other factors (e.g., cigarette smoking) (29, 30) on subsequent cancer risk may differ for radiotherapy compared with lower-dose radiation exposures.

Data on other (non-treatment) cancer risk factors are far too sparse in medical record-based studies, yet we know that most second cancers result from genetic, lifestyle and environmental risk factors, as shown in a recent study estimating that fewer than 10% of second solid cancers are due to radiotherapy in adulthood (30). Emerging studies therefore need to focus simultaneously on the multiple contributors to second cancers and the potential interactions among them. Richer data from electronic medical records and interconnected sources on well-defined populations should provide the information needed to elucidate the causes of second cancers and the long-term effects of high-dose fractionated radiation exposure.

GENETIC SUSCEPTIBILITY TO RADIATION

Some individuals may be more genetically susceptible to the effects of radiation than others, as seen in populations with certain rare hereditary disorders, such as ataxia telangiectasia. The known genetic variants associated with these cancer susceptibility syndromes affect a very small proportion of the general population. On the other hand, multiple genetic pathways have been implicated in studies of radiosensitivity (including DNA damage repair, radiation fibrogenesis, oxidative stress and endothelial cell damage) (31), so it is likely that some of the contribution to radiation susceptibility is polygenic, with elevated risk resulting from the inheritance of several low-penetrance risk alleles (the “common-variant-common-disease” model).

The few studies to date examining common genetic variants associated with risk of radiation-induced cancer have mainly employed the “candidate-gene” approach to examine whether single nucleotide polymorphisms (SNPs) affect risk. This method assumes prior knowledge of one or more functional SNPs. A series of nested case-control studies of breast cancer in U.S. radiologic technologists, for example, has suggested that common variants in genes involved in DNA damage repair (32, 33), apoptosis (34) and proliferation (35) may alter the risk of radiation-related breast cancer from diagnostic radiation procedures. However, none of these results have been convincingly replicated to date. This is not surprising given the challenges facing gene–radiation interaction studies. For one, sample sizes need to

be sufficiently large to detect interaction, particularly in the context of low-level radiation exposure. Additionally, high-quality exposure assessment for both radiation and potential confounding factors (such as chemotherapy) is essential to reduce misclassification. Finally, the complexity of the underlying biology makes it exceedingly difficult to identify true causal variants through the candidate gene method. The “genome-wide association study” (GWAS), which uses genetic markers (tag-SNPs) across the genome to identify regions of interest, is a more agnostic approach that has been successful in identifying novel cancer susceptibility regions for several cancer sites, and it may be informative in the context of radiation sensitivity.

Identifying genetically high-risk individuals to reduce radiation exposure to these individuals when possible remains a very pertinent research strategy. However, ascertaining this variation is not straightforward. It is essential that studies addressing this question have large sample sizes and high-quality exposure information, with sufficient power to adequately address variation in demographic and treatment factors. With the rapid advancement of technology to query the genome, studies of radiation-associated genetic susceptibility must carefully assess the available technologies and choose the technology appropriate for the specific study question(s) being asked.

CONCLUSION

We see ahead a continuing expansion of radiation exposure to the population from medical tests and treatments. Recent events in Japan also remind us that future nuclear accidents are a real threat. Cancer epidemiologists must respond by developing and adapting a variety of flexible research strategies. The most useful of these strategies fall into two broad frameworks. The first employs statistical modeling, both of the doses received and the cancer risks incurred, using the data we have accumulated from past studies. Risk projection, computational phantoms and newly discovered genetic susceptibility will play increasingly prominent roles. The complementary framework is field studies: directly measuring doses and cancer occurrence in groups who have been exposed, some from new treatment techniques, some from nuclear reactor accidents, and some from other sources. Both the modeling and the measuring approaches will engage a variety of scientific disciplines, and the ongoing comparison of the results of each will help direct the field and generate new research strategies.

REFERENCES

1. Land CE, Estimating cancer risks from low doses of ionizing radiation. *Science* 1980; 209:1197–203.
2. Health implications of fallout from nuclear weapons testing through 1961. Federal Guidance Report No 3. Washington, DC: Federal Radiation Council; 1962.
3. Little MP, Wakeford R, Kendall GM. Updated estimates of the proportion of childhood leukaemia incidence in Great Britain that may be caused by natural background ionising radiation. *J Radiol Prot* 2009; 29:467–82.
4. Berrington de Gonzalez A, Mahesh M, Kim KP, Bhargavan M, Lewis R, Mettler F, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. *Arch Intern Med* 2009; 169: 2071–7.
5. Cardis E, Krewski D, Boniol M, Drozdovitch V, Darby SC, Gilbert ES, et al. Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. *Int J Cancer* 2006; 119:1224–35.
6. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, et al. Solid cancer incidence in atomic bomb survivors: 1958–1998. *Radiat Res* 2007; 168:1–64.
7. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. *Radiat Res* 2002; 158:220–35.
8. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. *Radiat Res* 1995; 141:259–77.
9. Snyder WS, Fisher HL Jr, Ford MR, Warner GG. MIRD Pamphlet No. 5: Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. *J Nucl Med* 1969; 10:1–52.
10. Zankl M, Veit R, Williams G, Schneider K, Fendel H, Petoussi N, et al. The construction of computer tomographic phantoms and their application in radiology and radiation protection. *Radiat Environ Biophys* 1988; 27:153–64.
11. Lee C, Lee C, Lodwick D, Bolch WE. Development of hybrid computational phantoms of newborn male and female for dosimetry calculation. *Phys Med Biol* 2007; 52:3309–33.
12. Segars W, Sturgeon G, Mendonca S, Grimes J, Tsui B. 4D XCAT phantom for multimodality imaging research. *Med Phys* 2010; 37:4902.
13. Xu XG, Taranenkov V, Zhang J, Shi C. A boundary-representation method for designing whole-body radiation dosimetry models: pregnant females at the ends of three gestational periods – RPI-P3, -P6 and -P9. *Phys Med Biol* 2007; 52:7023–44.
14. Brenner AV, Tronko MD, Hatch M, Bogdanova TI, Olyinik VA, Lubin JH, et al. I-131 dose-response for incident thyroid cancers in Ukraine related to the Chernobyl accident. *Environ Health Perspect* 2011; 119:933–9.
15. Romanenko A, Bebesko V, Hatch M, Bazyka D, Finch S, Dyagil I, et al. The Ukrainian-American study of leukemia and related disorders among Chernobyl cleanup workers from Ukraine: I. Study methods. *Radiat Res* 2008; 170:691–7.
16. Furukawa K, Preston DL, Lonn S, Funamoto S, Yonehara S, Matsuo T, et al. Radiation and smoking effects on lung cancer incidence among atomic bomb survivors. *Radiat Res* 2010; 174:72–82.
17. Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, et al. Lung cancer after treatment for Hodgkin’s disease: focus on radiation effects. *Radiat Res* 2003; 159:161–73.
18. Howlader N, Noone A, Krapcho M, Neyman N, Aminou, Waldron W, et al., SEER Cancer Statistics Review, 1975–2008. Bethesda (MD): National Cancer Institute; http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER website, 2011.
19. In: New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000 (Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, et al, editors). NIH Publ. No. 05–5302. Bethesda (MD): National Cancer Institute; 2006.
20. Dores GM, Anderson WF, Beane Freeman LE, Fraumeni JF Jr, Curtis RE. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin’s lymphoma treated with radiotherapy. *Br J Cancer* 2010; 103:1081–4.

21. Lonn S, Gilbert ES, Ron E, Smith SA, Stovall M, Curtis RE. Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. *Cancer Epidemiol Biomarkers Prev* 2010; 19:464–74.
22. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. *J Clin Oncol* 2010; 28:4935–44.
23. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. *J Natl Cancer Inst* 2002; 94:182–92.
24. UNSCEAR, United Nations Scientific Committee on the Effects of Atomic Radiation, Sources and Effects of Ionizing Radiation. UNSCEAR 2006 Report to the General Assembly, with Scientific Annexes, Volume 1. New York: United Nations; 2008.
25. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. *Lancet* 2005; 365:2014–23.
26. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. *JAMA* 2003; 290:465–75.
27. Boice JD Jr, Day NE, Andersen A, Brinton LA, Brown R, Choi NW, et al. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. *J Natl Cancer Inst* 1985; 74:955–75.
28. Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia P, Mertens AC, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. *Ann Intern Med* 2004; 141:590–7.
29. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2006; 98:1528–37.
30. Berrington de Gonzalez A, Curtis R, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. *Br J Cancer* 2010; 102:220–6.
31. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. *Nat Rev Cancer* 2009; 9:134–42.
32. Bhatti P, Struwing JP, Alexander BH, Hauptmann M, Bowen L, Mateus-Pereira LH, et al. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. radiologic technologists. *Int J Cancer* 2008; 122:177–82.
33. Rajaraman P, Bhatti P, Doody MM, Simon SL, Weinstock RM, Linet MS, et al. Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. *Int J Cancer* 2008; 123:2713–6.
34. Bhatti P, Doody MM, Rajaraman P, Alexander BH, Yeager M, Hutchinson A, et al. Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists. *Radiat Res* 2010; 173:214–24.
35. Sigurdson AJ, Bhatti P, Doody MM, Hauptmann M, Bowen L, Simon SL, et al. Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. radiologic technologists. *Cancer Epidemiol Biomarkers Prev* 2007; 16:2000–7.